View Post

Groundbreaking combo therapy data presented at SITC 2015

In In The News by Barbara Jacoby

Preliminary Results from Phase I/II Study of Epacadostat in Combination with Pembrolizumab Demonstrates 53% Overall Response Rate across a Number of Cancer Types Phase I/II dose-escalation and dose-expansion study presented at the SITC Annual Meeting included patients with advanced melanoma, renal cell carcinoma (RCC), transitional cell carcinoma (TCC), non-small cell lung cancer (NSCLC), endometrial adenocarcinoma (EA), or squamous cell carcinoma …